Epigenomics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.339227 million compared to EUR 0.899 million a year ago. Net loss was EUR 4.46 million compared to EUR 1,730.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.61 EUR | 0.00% | -2.72% | -14.81% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.81% | 1.51M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 377M |
- Stock Market
- Equities
- ECX Stock
- News Epigenomics AG
- Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023